Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer
Table 3
Correlation between CCRT or chemotherapy and clinicopathologic features in 65 locally advanced/metastatic gastric cancer patients.
Total N = 65
CCRT N = 30 (%)
Chemotherapy N = 35 (%)
value
Age, years
≧65 years
33 (50.8)
10 (33.3)
23 (65.7)
0.013
<65 years
32 (49.2)
20 (66.7)
12 (34.3)
Gender
Male
42 (64.6)
22 (73.3)
20 (57.1)
0.202
Female
23 (35.4)
8 (36.7)
15 (42.9)
Tumor size
<5 cm
36 (55.4)
13 (43.3)
23 (65.7)
0.085
≧5 cm
29 (44.6)
17 (56.7)
12 (34.3)
Clinical T status
T4
47 (72.3)
21 (70.0)
26 (74.3)
0.784
T3
18 (27.7)
9 (30.0)
9 (25.7)
Clinical N status
N1
10 (15.4)
5 (16.7)
5 (14.3)
1.000
N2 + N3
55 (84.6)
25 (83.3)
30 (85.7)
Vascular invasion
Positive
10 (43.5)
3 (33.3)
7 (50.0)
0.680
Negative
13 (56.5)
6 (66.7)
7 (50.0)
Perineural invasion
Positive
11 (47.8)
4 (44.4)
7 (50.0)
1.000
Negative
12 (52.2)
5 (55.6)
7 (50.0)
Clinical TNM stage
Stage III
41 (63.1)
20 (66.7)
21 (60.0)
0.615
Stage IV
24 (36.9)
10 (33.3)
14 (40.0)
Pretreatment CEA (ng/ml)
≧5
16 (24.6)
4 (13.3)
12 (34.3)
0.082
<5
49 (75.4)
26 (86.7)
23 (65.7)
Posttreatment CEA (ng/ml)
≧5
20 (30.8)
9 (30.0)
11 (31.4)
1.000
<5
45 (69.2)
21 (70.0)
24 (68.6)
Response rate
CR + PR
18 (27.7)
10 (33.3)
8 (22.9)
0.411
SD + PD
47 (72.3)
20 (66.7)
27 (77.1)
Disease control rate
CR + PR + SD
48 (73.9)
25 (83.3)
23 (65.7)
0.158
PD
17 (26.1)
5 (16.7)
12 (34.2)
R0/R1 resection
Yes
25 (35.5)
11 (36.7)
14 (40.0)
0.804
No
40 (61.5)
19 (63.3)
21 (60.0)
Surgical outcomes (N = 25) operating time (median, minute)
